Head, Division of Hematologic Malignancy Department of Medicine Memorial Sloan Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Location: New York, New York
Internal Number: 72574
The people of Memorial Sloan Kettering Cancer Center (MSK) are united by a singular mission: ending cancer for life. Our specialized care teams provide personalized, compassionate, expert care to patients of all ages. Informed by basic research done at our Sloan Kettering Institute, scientists across MSK collaborate to conduct innovative translational and clinical research that is driving a revolution in our understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is dedicated to training the next generation of scientists and clinicians, who go on to pursue our mission at MSK and around the globe. One of the world's most respected comprehensive centers devoted exclusively to cancer, we have been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for more than 30 years.
Vaccination for COVID-19 and Influenza (flu) is mandatory for all MSK staff. Staff are considered fully vaccinated upon completion of a primary vaccination series for COVID-19 (i.e., one dose of a single dose vaccine or a final dose of a multi-dose vaccine series). Exceptions from the COVID-19 and Influenza (flu) vaccine requirements are permitted for those who request and receive an approved medical, religious, or fully remote exemption. Requests for exemption can take up to two weeks to review. Vaccination or an approved exemption is required to start work.
The Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK) is seeking an exceptional physician investigator and inspirational leader to serve as Head of the Division of Hematologic Malignancies. The Division of Hematologic Malignancies is comprised of over 90 faculty. Direct reports will include Service Chiefs of MSK's Adult Bone Marrow Transplant, Cellular Therapy, Leukemia, Lymphoma, Myeloma and the Benign Hematology Services. These faculty deliver care in New York City as well as across MSK's network that extends from Southern New Jersey to Eastern Long Island. MSK's expertise is increasingly sought by patients beyond our local region, including internationally. Increased work on digital platforms to support this work is expanding.
The Division of Hematologic Malignancies is dedicated to treating patients with the full spectrum of malignant and premalignant blood disorders. Division faculty perform nearly 600 bone marrow and stem cell transplants each year, and a rapidly growing number of patients are treated with immune effector cells. Division faculty deliver over 85,000 outpatient visits with 6,500 new patients per year. Division faculty include individuals with both wet and dry-lab based research programs dedicated to both fundamental mechanistic discovery, pharmacology, and to clinical translation. Faculty lead a portfolio of over 450 trials that include both investigator-initiated and industry-sponsored studies. Division faculty have led trials that resulted in many FDA approvals of new treatment strategies across the spectrum of blood cancers. They have been highly successful in attracting federal and foundation funding as well as philanthropy to support their efforts.
The Division Head will have programmatic oversight and responsibility for the Hematologic Malignancy Service Chiefs and their Services. S/he will work with these leaders to shape the scientific, strategic and programmatic priorities for the Division, and will foster clinical, and scientific excellence, talent acquisition and retention, the clinical trial portfolio, grant funding, professional development, mentorship and teaching. S/he will report to the Chair of the Department of Medicine but will work closely with an array of MSK's senior leaders to support the full spectrum of clinical care, training and transdisciplinary research in Hematologic Malignancies. The Division Head will partner with the Chief Scientific Officer, Deputy Physician in Chief for Translational Research, Deputy Physician in Chief for Clinical Research, Sloan Kettering Institute Program Chairs, the Chair of the Human Oncology and Pathogenesis Program (HOPP), and the Pathology Department Chair to nurture a world-class program in Hematologic Malignancies. The Division Head will also work closely with MSK's Hospital President, Chief Nursing and Chief Physician Executives to ensure optimal care and to build programs that meet the current and future needs of patients with or at risk for hematologic malignancies.
The ideal candidate for this key institutional leadership role is an individual with a vibrant and innovative research program in any field of hematologic malignancies who also has leadership skills and is able to set and share a strategic vision, promote team science and foster a collaborative approach to mentoring trainees and faculty. The ideal candidate is a physician-scientist with expertise in both the delivery of top-quality clinical care and advancing understanding of the biology of these diseases and the development of novel therapeutic strategies for the treatment of hematologic malignancies. Individuals who have the ability to set strategic vision, inspire teams and collaborate well across disciplinary boundaries are most likely to be successful in this key institutional leadership role. The Division Head will serve as a key leader at MSK to chart the future course as the organization embraces many contemporary challenges facing medicine such as integration of artificial intelligence into clinical care and delivering care on a global scale using digital health platforms.
Interested candidates should apply by sending a brief statement of prior experience, research interests and a CV to Ross Levine, Deputy Physician in Chief for Translational Research, MSK [email protected] and cc Valentina Salkow, Manager, Academic Recruitment, [email protected].
Expected salary range is $650K-$800K for this role.
Physician compensation is based on multiple variables. This range represents annual salary only and does not include supplemental performance-based pay or any one-time payments.
MSK is an equal opportunity and affirmative action employer committed to diversity and inclusion in all aspects of recruiting and employment. All qualified individuals are encouraged to apply and will receive consideration without regard to race, color, gender, gender identity or expression, sexual orientation, national origin, age, religion, creed, disability, veteran status or any other factor which cannot lawfully be used as a basis for an employment decision.
Federal law requires employers to provide reasonable accommodation to qualified individuals with disabilities. Please tell us if you require a reasonable accommodation to apply for a job or to perform your job. Examples of reasonable accommodation include making a change to the application process or work procedures, providing documents in an alternate format, using a sign language interpreter, or using specialized equipment.
MSK is the world's oldest and largest private institution devoted to the prevention, treatment, and cure of cancer. Founded in 1884, MSK has long been a leader in early detection, precise diagnosis, and individually tailored treatments for cancer. We continue to drive innovations as one of 52 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.
The close collaboration between our scientists and physicians is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future scientists and physicians, and the knowledge and experience they gain at MSK has an impact on cancer treatment and biomedical research around the world.